No Data
Tryptamine Therapeutics Issues 47 Million Unquoted Options
Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study
Tryptamine Therapeutics Doses First Patient in IV-infused Psilocin Phase 1b Study
Tryptamine to Plug $6M Placement Funding Into Acceleration of IV-infused Psilocybin Treatment Trials
Tryptamine Therapeutics A$6 Million Placement Cornerstoned by Merchant Biotech Fund and Dr Daniel Tillett | ASX:TYP, OTC:TYPTF
Tryptamine Therapeutics Plans Capital Raising Amid Trading Halt
No Data